New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:22 EDTBCR, MDTC.R. Bard Lutonix balloon has 50% chance for approval at best, says Wells Fargo
After reviewing briefing materials posted to the FDA's website for an upcoming advisory committee meeting, Wells Fargo said it expects a "very tough" panel for C.R. Bard's (BCR) Lutonix drug-coated balloon and puts the chance of approval for the product at 50% "at best." Additionally, the firm does not think Bard's data is competitive with stents, which are the standard of care, or with data on Medtronic's (MDT) competing balloon.
News For BCR;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:37 EDTBCRC.R. Bard upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.
April 23, 2015
17:40 EDTBCRC.R. Bard sees Q2 EPS $2.15-$2.19, consensus $2.18
Subscribe for More Information
17:29 EDTBCRC.R. Bard sees FY15 EPS $8.95-$9.05, consensus $9.00
Guidance provided on Q1 earnings conference call.
16:18 EDTBCRC.R. Bard reports Q1 adjusted EPS $2.10, consensus $2.07
Reports Q1 revenue $819.7M, consensus $813.88M.
April 21, 2015
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 17, 2015
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
April 14, 2015
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information
April 13, 2015
17:13 EDTMDTIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:10 EDTMDTIBM establishes a Watson Health Cloud
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use